- No FAQs found
- ABL Kinase Domain Mutation in CML, Cell-based
- ABO Group and Rh Type
- Acid-Fast Bacillus (AFB) Identification, Sequencing and Stain, Paraffin Block
- ADAMTS13 Activity with Reflex to ADAMTS13 Inhibitor
- Alcohol Metabolites, Quantitative, Urine
- Alpha-Globin Common Mutation Analysis
- Alpha-Globin Gene Deletion or Duplication
- Alpha-Globin Gene Sequencing
- Anti-Müllerian Hormone AssessR™
- Anti-PF4 and Serotonin Release Assay (SRA) for Diagnosing Heparin-induced Thrombocytopenia/Thrombosis (HIT/HITT)
- Antiphospholipid Antibodies
- ASCVD Risk Panel with Score
- Autoimmune Epilepsy Evaluation
- Autoimmune Diseases, Tests for
- B-cell and T-cell Clonality Assays by PCR
- B-Type Natriuretic Peptide (BNP)
- BCR-ABL1 Gene Rearrangement, Quantitative PCR
- Beta-Globin Complete
- BRCAvantage®, Ashkenazi Jewish Screen
- BRCAvantage®, Rearrangements
- BRCAvantage™, Comprehensive
- BRCAvantage™, Single Site
- CDH1 Sequencing and Deletion/Duplication
- Clostridium difficile Diagnostic Testing
- C1 Inhibitor, Protein and Functional Tests
- Calreticulin (CALR) Mutation Analysis
- Carbapenem Resistant Enterobacteriaceae Culture Screen
- Cardio IQ Lipoprotein Fractionation, Ion Mobility
- Cervical Cancer, TERC, FISH
- CFvantage® Cystic Fibrosis Expanded Screen
- Chlamydia trachomatis, TMA
- Chlamydia trachomatis/Neisseria gonorrhoeae RNA, TMA
- Chromosomal Microarray, POC, ClariSure®, Oligo-SNP
- Chromosomal Microarray, Postnatal, ClariSure® Oligo-SNP
- Chromosome Analysis and AFP with Reflex to AChE, Fetal Hgb, Amniotic Fluid
- Chromosome Analysis, Amniotic Fluid
- Chromosome Analysis, Blood
- Chromosome Analysis, Blood with Reflex to Postnatal, ClariSure® Oligo-SNP Array
- Chromosome Analysis, Chorionic Villus Sample
- Chromosome Analysis, High Resolution
- Chromosome Analysis, High Resolution with Reflex to Postnatal, ClariSure® Oligo-SNP Array
- Chromosome Analysis, Mosaicism
- Chromosome Analysis, Neonatal Blood
- Chromosome Analysis, Sister Chromatid Exchange
- Chromosome Analysis, Tissue
- Chromosome DEB Assay for Fanconi anemia
- Chronic Lymphocytic Leukemia (CLL) - Diagnostic and Prognostic Testing
- Culture, Fungus
- Culture, Urine, Routine
- Cystic Fibrosis Screen
- Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) PCR
- D-Dimer, Quantitative
- Dementia, Secondary Causes
- Dengue Virus Testing
- Diabetes Risk Panel with Score and Cardio IQ® Diabetes Risk Panel with Score
- Drug Testing, General Toxicology (Blood, Urine, or Serum)
- Drug Toxicology Alcohol Metab, QN, Oral Fluid
- Drug Toxicology Monitoring, Oral Fluid Testing
- Factor V (Leiden) Mutation Analysis
- Familial Mediterranean Fever Mutation Analysis
- First Trimester Screen, hCG
- First Trimester Screen, Hyperglycosylated hCG (h-hCG)
- FISH, Angelman
- FISH, MET Amplification
- FISH, Myeloma, 17p-, rea 14q32 with Reflexes
- FISH, Prader-Willi
- FISH, Prenatal Screen
- No FAQs found
- HCV Genotyping
- Helicobacter pylori (H pylori) Antibody Discontinuation
- Heparin, Anti-Xa
- Hepatitis B Surface Antibody, Quantitative
- Hepatitis B Surface Antigen, Quantitative, Monitoring
- Hepatitis C Antibody with Reflex to HCV RNA, PCR with Reflex to Genotype
- Hepatitis C Viral RNA Genotype 1 NS5A Drug-resistance
- Hepatitis C Viral RNA Genotype 3 NS5A Drug Resistance
- Hepatitis C Viral RNA NS3 Drug Resistance
- Hepatitis C, RNA, Quantitative, PCR
- Hereditary Cancer Panels: MYvantageTM Hereditary Comprehensive Cancer Panel and GIvantageTM Hereditary Colorectal Cancer Panel
- Hereditary Hemochromatosis DNA Mutation Analysis
- Herpes Simplex Virus (HSV) Type-Specific IgG Antibodies
- Herpes Simplex Virus Type 2 (HSV-2) IgG Inhibition, ELISA
- HIV-1 Coreceptor Tropism, Proviral DNA
- HIV-1 Coreceptor Tropism, Ultradeep Sequencing
- HIV-1 Integrase Genotype
- HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes
- HPV mRNA E6/E7
- Influenza A and B Antigen, Immunoassay
- Influenza Type A and B Antibodies
- Insulin, Intact, LC/MS/MS
- Integrated Screen, Part 1
- Integrated Screen, Part 2
- Intrinsic Factor Blocking Antibody
- No FAQs found
- No FAQs found
- Maternal Serum AFP
- Melanoma, BRAF V600E and V600K Mutation Analysis, THxID®
- Metanephrines, Fractionated, Free, LC/MS/MS, Plasma
- Methylenetetrahydrofolate Reductase (MTHFR), DNA Analysis
- Microalbumin (Urinary Albumin Excretion)
- Pain Management and CYP2D6/CYP2C19
- Pain Management, Naltrexone, Quantitative, Urine
- Partial Thromboplastin Time, Activated (aPTT)
- Penta Screen
- PIK3CA Mutation Analysis
- Platelet Antibody Screen (Indirect)
- PNH with FLAER (High Sensitivity)
- Prothrombin Time with INR
- PTH, Intact and Calcium
- Streptococcus pneumoniae (Pneumococcal) Antibody Tests
- Saccharomyces cerevisiae Antibodies (ASCA) (IgG, IgA)
- Sequential Integrated Screen, Part 1
- Sequential Integrated Screen, Part 2
- Serum Integrated Screen, Part 1
- Serum Integrated Screen, Part 2
- Serum Pregnancy Tests
- Sickle Cell Screen
- Stepwise, Part 1
- Stepwise, Part 2
- SureSwab® Trichomonas vaginalis RNA, Qualitative TMA
- SureSwab®, Candidiasis, PCR
- TP53 Sequencing and Deletion/Duplication
- T4, Free
- Tamoxifen and Metabolites, LC-MS/MS
- Testosterone Testing
- Total Testosterone, LC/MS/MS
- Triple Screen
- No FAQs found
- No FAQs found
- No FAQs found
BRCAvantage™, Ashkenazi Jewish ScreenTest code(s) 91864
This is an outdated version of this FAQ. It was effective 10/15/2013 to 04/23/2015.
The current version is available here.
Question 1. What is this test for?
This test is designed to detect the 3 mutations known to be more common in people of Ashkenazi (Eastern European) Jewish descent: 185delAG and 5382insC in the BRCA1 gene and 6174delT in the BRCA2 gene.
About 1 in 40 Ashkenazi Jewish people has 1 of these 3 “founder” mutations. This carrier frequency is significantly higher than that in the general population (1 in 700).1-3 Thus, testing for the 3 mutations is a cost-effective way of identifying Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.
For men and women of other ancestries, other BRCAvantage tests may be more appropriate. For more information or to discuss a family history with a Quest Diagnostics genetic counselor, please call 866-GENE-INFO.
Question 2. To whom should this test be offered?
Generally, men and women of Ashkenazi (Eastern European) Jewish ancestry with either or both of the following:
- A personal diagnosis of breast cancer, bilateral breast cancer, and/or ovarian cancer at any age
- A strong family history of breast and/or ovarian cancer
The National Comprehensive Cancer Network (NCCN) has more detailed criteria for selecting individuals for genetic testing (http://www.nccn.org/professionals/physician_gls/f_guidelines.asp). The guidelines strongly recommend genetic counseling for the patient before ordering this test. The person in the family with the earliest diagnosis of breast and/or ovarian cancer should be tested first whenever possible.
For more information or to discuss a family history with a Quest Diagnostics genetic counselor, please call 866-GENE-INFO.
Question 3. Is there a better test for my patient?
If the patient is not of Ashkenazi Jewish descent, this test should not be ordered. Depending on the patient's personal and family histories, BRCAvantage™, Comprehensive (test code 91863) may be appropriate.
If the patient is of Ashkenazi Jewish descent and the familial mutation is not 1 of the 3 Ashkenazi Jewish founder mutations, consider testing the patient for both the founder mutations (BRCAvantage™, Ashkenazi Jewish Screen [test code 91864]) and the familial mutation (BRCAvantage™, Single Site [test code 91865]). For more information or to discuss a family history with a Quest Diagnostics genetic counselor, please call 866-GENE-INFO.
Question 4. My patient has a positive result. What does this mean?
If your patient tests positive for a deleterious BRCA1 or BRCA2 mutation, he/she is at significantly increased risk for developing breast and ovarian cancer and other related cancers compared to the general population.
The NCCN provides up-to-date surveillance and management recommendations for mutation carriers (http://www.nccn.org/professionals/physician_gls/f_guidelines.asp). Referral to an oncology center experienced in treating patients with a BRCA1 or BRCA2 mutation might be considered to discuss options. These options include increased surveillance, chemoprevention, and prophylactic surgery.
Question 5. My patient has a negative result. What does this mean?
Patient with a known family history of 1 of the 3 Ashkenazi Jewish mutations
None of the 3 Ashkenazi Jewish mutations was found. The patient’s risk of breast and ovarian cancer is equivalent to that of the general population.
Patient previously diagnosed with breast or ovarian cancer
None of the 3 Ashkenazi Jewish mutations was found. Consider the BRCAvantage, Comprehensive test (test code 91863) if the patient meets clinical criteria. Your patient’s risk of recurrence is based on his/her personal and family histories of cancer. In some instances, it may be appropriate to test for other hereditary forms of cancer. Call 866-GENE-INFO to discuss possible further studies.
Patient not previously diagnosed with breast or ovarian cancer, but with a family history of breast and/or ovarian cancer
None of the 3 Ashkenazi Jewish mutations was found. Testing of an affected family member is recommended for proper risk assessment. Your patient’s risk of cancer is based on his/her personal and family history of cancer. Consider the BRCAvantage, Comprehensive test (test code 91863) if the patient meets clinical criteria. In some instances, it may be appropriate to test for other hereditary forms of cancer. Call 866-GENE-INFO to discuss possible further studies.
- Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet. 1997;60:496-504.
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Genetic/familial high-risk assessment: breast and ovarian. V4.2013. http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed August 15, 2013.
- American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol. 2009;113:957-966.
Document FAQS.121 Revision: 0